论文部分内容阅读
用链亲和素-胶体金原位杂交(ISH-SAG)检测了52例急性白血病和4例正常骨髓细胞的多药耐药基因(MDR1)表达。全部52例急性白血病中25例(48.1％)MDR1呈阳性表达,其中初治组MDR1阳性12例(43％),复发难治组MDR1阳性11例(78.6％),两组相差显著P<0.05,完全缓解期MDR1阳性2例(20％)。疗效分析发现MDR1表达与临床缓解率密切相关,MDR1阳性组完全缓解率(52.1％)明显低于MDR1阴性组(88.2％),P<0.05。本研究还同时用免疫细胞化学法检测了P-糖蛋白(Pgp)的表达,两者结果的一致率为84.6％(40/52)。初步结果表明:对检测MDR1检测简便、敏感和特异,为多药耐药的临床研究提供了一个新方法。用ISH-SAG检测MDR1,可预测白血病对化疗的敏感性及预后,并为制定化疗方案提供依据。
The expression of multidrug resistance gene (MDR1) in 52 acute leukemia and 4 normal bone marrow cells was detected by streptavidin-colloidal gold in situ hybridization (ISH-SAG). In all 52 cases of acute leukemia, MDR1 was positively expressed in 25 cases (48.1%). Among them, 12 cases (43%) were MDR1 positive in the untreated group and 11 cases (78.6%) were MDR1 positive in the relapsed and refractory group. The difference between the two groups was significant P<0.05. Two cases of MDR1 positive (20%) were completely remissioned. The efficacy analysis showed that the expression of MDR1 was closely related to the clinical remission rate. The complete remission rate of MDR1 positive group (52.1%) was significantly lower than that of MDR1 negative group (88.2%), P<0.05. In this study, the expression of P-glycoprotein (Pgp) was also detected by immunocytochemistry. The agreement rate of the two results was 84.6% (40/52). Preliminary results indicate that the detection of MDR1 is simple, sensitive, and specific, providing a new method for clinical research of multidrug resistance. The detection of MDR1 by ISH-SAG can predict the sensitivity and prognosis of leukemia in chemotherapy, and provide basis for formulating chemotherapy regimens.